论文部分内容阅读
目的 探讨E Cadherin(ECD)、α Catenin在肾癌中的表达及临床意义。 方法 采用免疫组化方法检测 41例肾癌标本中ECD、α Catenin的表达 ,分析其与临床、病理及转移、复发和预后的关系。 结果 肾癌中ECD、α Catenin低表达或无表达与肾癌的临床分期显著相关 (P均 <0 .0 5)。不同病理类型肾癌的表达差别无显著性意义。α Catenin低表达的病人术后 3年生存率低 ,提示患者预后不良。 结论 ECD、α Catenin表达降低或无表达提示肾癌具有恶性生物学行为 ,与肿瘤浸润转移相关 ,检测α Catenin对肿瘤病人预后评估有一定意义。
Objective To investigate the expression of E-cadherin (ECD) and α Catenin in renal cell carcinoma and its clinical significance. Methods Immunohistochemical method was used to detect the expression of ECD and α Catenin in 41 cases of renal cell carcinoma, and its relationship with clinical, pathological, metastasis, recurrence and prognosis was analyzed. Results The low or no expression of ECD and α Catenin in renal cell carcinoma was significantly associated with the clinical stage of renal cell carcinoma (all P <0.05). There was no significant difference in the expression of different pathological types of renal cell carcinoma. The 3-year survival rate of patients with low expression of α Catenin is low, suggesting that patients with poor prognosis. Conclusions The decreased or no expression of ECD and α Catenin suggests that renal cancer has malignant biological behavior, which is correlated with tumor invasion and metastasis. It is of certain significance to detect α Catenin in the prognosis evaluation of tumor patients.